FDA Rejects Regeneron’s sBLA to Extend EYLEA HD Dosing Interval
Regeneron’s proposal to lengthen EYLEA HD dosing intervals to 24 weeks hits a CRL roadblock. The wait for extended treatment…
FDA Approves the First Anti-VEGF Port Delivery System for Diabetic Macular Edema
Got a patient with DME? Say goodbye to the monthly jab—Susvimo, the first continuous drug delivery system for DME just…
latest posts
